妊娠期COVID-19凝血病:关键综述、初步建议及ISTH登记——ISTH SSC女性健康委员会通讯
本文由国际血栓与止血学会(ISTH)女性健康问题小组委员会组织专家协作完成,经结构化文献检索并评估现有及新兴证据质量后形成共识文件。由于缺乏针对妊娠期SARS-CoV-2感染管理的随机临床试验数据,且现有非妊娠和妊娠人群研究经Newcastle-Ottawa量表评估为中等至高偏倚风险,专家组制定了妊娠期COVID-19凝血病的初步建议,并建立了国际登记以收集数据支持管理。文中强调妊娠期特有的止血问题,并指出需要针对该特定人群的诊疗指导。
要点
- 大型系统评价和Meta分析纳入2567例妊娠女性,7%需重症监护入院,孕产妇死亡率约1%,围产期死亡率低于1%。
- 非妊娠人群COVID-19相关凝血病(包括弥散性血管内凝血和静脉血栓栓塞症)文献快速增加,但妊娠期报道极少,缺乏针对该人群的诊疗指导。
- ISTH女性健康问题小组委员会经专家协作、文献检索和证据质量评估后,制定妊娠期COVID-19凝血病初步建议。
- 现有非妊娠和妊娠人群研究经Newcastle-Ottawa量表评估为中等至高偏倚风险,且无随机临床试验数据。
- 已建立国际登记以收集数据支持妊娠期COVID-19及相关凝血病的管理。
适用人群与场景
- 妊娠期感染SARS-CoV-2并出现凝血病或血栓并发症的女性。
研究设计与关键结果
- 制定机构:国际血栓与止血学会(ISTH)女性健康问题小组委员会;方法:专家协作、结构化文献检索、证据质量评估,经小组委员会审阅、批评和批准。
- 基于非妊娠和妊娠人群已发表研究(Newcastle-Ottawa量表评估为中等至高偏倚风险),承认缺乏妊娠期SARS-CoV-2感染管理的随机临床试验数据,形成支持妊娠期COVID-19凝血病指导文件的共识。
- 制定了协助管理COVID-19影响的妊娠女性合并凝血病或血栓并发症的初步建议。
- 建立了国际登记以收集数据支持妊娠期COVID-19及相关凝血病的管理。
- 大型系统评价和Meta分析(纳入2567例妊娠女性)显示:7%需重症监护入院,孕产妇死亡率约1%,围产期死亡率低于1%。
证据类型、等级与局限
- 证据类型:专家共识/指导文件,基于结构化文献检索和证据质量评估;现有非妊娠和妊娠人群研究经Newcastle-Ottawa量表评估为中等至高偏倚风险。
- 局限:缺乏针对妊娠期SARS-CoV-2感染管理的随机临床试验数据。
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- ISTH SSC for Women's Health Communication: COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry(发表于J Thromb Haemost)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Novel coronavirus (SARS-CoV-2), which causes COVID-19, has thus far affected more than 15 million individuals, resulting in more than 600 000 deaths worldwide, and the number continues to rise. In a large systematic review and meta-analysis of the literature including 2567 pregnant women, 7% required intensive care admission, with a maternal mortality ~1% and perinatal mortality below 1%. There has been a rapid increase in publications on COVID-19-associated coagulopathy, including disseminated intravascular coagulopathy and venous thromboembolism, in the non-pregnant population, but very few reports of COVID-19 coagulopathy during pregnancy; leaving us with no guidance for care of this specific population.
METHODS: This is a collaborative effort conducted by a group of experts that was reviewed, critiqued, and approved by the International Society on Thrombosis and Haemostasis Subcommittee for Women's Health Issues in Thrombosis and Hemostasis. A structured literature search was conducted, and the quality of current and emerging evidence was evaluated. Based on the published studies in the non-pregnant and pregnant population with a moderate to high risk of bias as assessed by Newcastle-Ottawa scale and acknowledging the absence of data from randomized clinical trials for management of pregnant women infected with SARS-CoV-2, a consensus in support of a guidance document for COVID-19 coagulopathy in pregnancy was identified.
RESULTS AND CONCLUSIONS: Specific hemostatic issues during pregnancy were highlighted, and preliminary recommendations to assist in the care of COVID-19-affected pregnant women with coagulopathy or thrombotic complications were developed. An international registry to gather data to support the management of COVID-19 and associated coagulopathy in pregnancy was established.
参考来源
- Kadir RA, Kobayashi T, Iba T, et al. COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry-Communication from the ISTH SSC for Women's Health. J Thromb Haemost. 2020. PMID: 32846051. doi:10.1111/jth.15072
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。